Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2019 09:00 ET | Source: MannKind

MannKind to Present at the JMP Securities Life Sciences Conference

WESTLAKE VILLAGE, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
June 09, 2019 14:00 ET | Source: MannKind

MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions

WESTLAKE VILLAGE, Calif., June 09, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder...
June 03, 2019 08:00 ET | Source: MannKind

Pó para inalação Afrezza® (insulina humana) aprovado no Brasil

WESTLAKE VILLAGE, Califórnia e BELO HORIZONTE, Brasil, June 03, 2019 (GLOBE NEWSWIRE) -- A MannKind Corporation (Nasdaq:MNKD) e a BIOMM SA (BVMF:BIOM3) anunciaram hoje que o Pó para Inalação...
June 03, 2019 08:00 ET | Source: MannKind

Afrezza® (insulin human) Inhalation Powder Approved in Brazil

WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) and BIOMM SA (BVMF:BIOM3) today announced that Afrezza® (insulin human)...
May 16, 2019 16:01 ET | Source: MannKind

MannKind Announces Afrezza® Distribution Agreement in Australia

WESTLAKE VILLAGE, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the...
May 07, 2019 08:00 ET | Source: MannKind

MannKind Corporation Reports 2019 First Quarter Financial Results

1Q 2019 Total Revenues of $17.4 million 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q 2018 1Q 2019 Collaborations and Services Revenue was $12.4 million 1Q 2019 net loss per share $(0.08)...
April 30, 2019 09:00 ET | Source: MannKind

MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019

WESTLAKE VILLAGE, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management will...
April 25, 2019 09:45 ET | Source: MannKind

MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)

WESTLAKE VILLAGE, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be presented...
April 02, 2019 06:00 ET | Source: MannKind

MannKind to Present at the H.C. Wainwright Global Life Sciences Conference

WESTLAKE VILLAGE, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...
April 01, 2019 06:00 ET | Source: MannKind

MannKind Receives $12.5 Million Milestone Payment from United Therapeutics

WESTLAKE VILLAGE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its...